

Anti-CD19 & CD3 Reference Antibody (Blinatumomab)

Catalog # APR11617

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P15391 & P07766
Reactivity	Human
Clonality	Bispecific
Isotype	BiTE

Additional Information


Target/Specificity	CD19,CD3
Expression system	CHO

Protein Information

Images





Anti-CD19 & CD3 Reference Antibody (Blinatumomab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 98.26%, determined by SEC-HPLC.

Blinatumomab bound to CD19 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP), and read OD450. As shown in fig, Blinatumomab bound to in human CD19-His, and the EC50 was 0.370 nM.



Co-incubation of Blinatumomab with Jurkat cells, then with the addition of hu-CD19-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Blinatumomab was able to activate the NF-AT signaling pathway.



The detected molecular weight of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 53.81 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.